Summary of Key Points
WuXi AppTec's stock prices have recently strengthened in both the Hong Kong and A-share markets: its Hong Kong stock reached a record high of HK$204.2 per share, with a market value exceeding HK$600 billion, while its A-share price approached a historical peak of RMB 166.66 per share. There are two main reasons for this: firstly, a preliminary injunction approved by a U.S. court has temporarily alleviated the negative impact of being included in the 1260H list; secondly, the company's strong fundamentals, driven by new business opportunities (such as oligonucleotide and peptide drug orders), have exceeded expectations, leading to an upward revision of its revenue targets for 2026 and a significant increase in market confidence.
I. The U.S. Injunction Controversy Has Subsided, Providing Peace of Mind for Shareholders
In June this year, WuXi AppTec was included in the U.S. Department of Defense's 1260H list, which raised concerns about potential restrictions on its overseas operations. The company responded swiftly by filing a lawsuit against the Department of Defense and requesting a preliminary injunction to temporarily prevent the implementation of these restrictions. On August 7, the U.S. court approved the injunction, meaning that the company will not be immediately affected by this listing until the litigation is resolved. This news quickly dispelled previous concerns and propelled its stock price upward.
II. Performance Outpaces the COVID-19 Period, with Enhanced Profitability
WuXi AppTec's last record-high stock price was at the end of 2021, during the COVID-19 pandemic, when it benefited from orders for COVID-19-related drugs. However, its current performance is even more impressive:
- Revenues for 2025 are expected to reach RMB 45.46 billion, with a net profit of RMB 19.15 billion, both exceeding the peak levels seen during the pandemic;
- The first half of this year was even more outstanding, with revenues of RMB 28.897 billion (a year-on-year increase of 38.9%) and a net profit of RMB 11.08 billion (a year-on-year increase of 29.4%), marking the first time the company has reported a net profit in excess of RMB 10 billion for the first half of the year.
This indicates that the company is now generating substantial profits without relying on COVID-19-related activities, demonstrating its solid financial foundation.
III. New Business Drivers: Transitioning from COVID-19 Dependence to Sustainable Growth
While COVID-19-related orders were a major source of revenue in the past, the company has now shifted its focus to oligonucleotide and peptide drugs—two emerging areas in the pharmaceutical industry. Additionally, WuXi AppTec's "CRDMO" (Contract Research, Development, and Manufacturing Organization) model has been highly effective, providing customers with end-to-end services from early research to production. This approach encourages long-term collaborations and more stable orders.
IV. Revised Revenue Targets for Greater Growth Potential
The company has raised its revenue forecast for 2026 from RMB 51.3-53 billion to RMB 58.5-60.5 billion, with growth rates increasing from 18-22% to 35-39%. Such a significant revision reflects the company's confidence in having sufficient orders in hand. Investors, seeing this optimism about its future prospects, are willing to buy its stock, which in turn drives up its price.
In summary, WuXi AppTec's recent record-high stock prices are not accidental. In the short term, the resolution of the U.S. injunction has provided relief; in the long term, the company's strong performance and new business initiatives, along with clear growth prospects, have encouraged investors to support its stock price.